Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase 1/2 1

Status

Recruiting 9Unknown 7Completed 6Not yet recruiting 4Active not recruiting 4Withdrawn 1Terminated 1

Sponsor Class

UNKNOWN 3OTHER 3OTHER_GOV 1

Study Type

Interventional 7

Sponsor

Cancer Type

Breast 7

Conditions

Breast Neoplasms 47Carcinoma, Hepatocellular 9Triple Negative Breast Neoplasms 7Stomach Neoplasms 6Inflammatory Breast Neoplasms 6Lymphoma, Large B-Cell, Diffuse 4Urinary Bladder Neoplasms 3Non-Muscle Invasive Bladder Neoplasms 3Esophageal Neoplasms 3Recurrence 2Lymphoma 2Breast Neoplasms, Male 2Breast Diseases 2Upper Tract Urothelial Carcinoma 1Thymoma 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Complications 1Pancreatic Neoplasms 1Oesophagogastric Cancer 1Neoplastic Cells, Circulating 1Neoplasms, Unknown Primary 1Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lung Neoplasms 1Liver Neoplasms 1Leiomyosarcoma 1

Interventions

Carboplatin 15camrelizumab 11Capecitabine 11130-nm albumin-bound paclitaxel 10pembrolizumab 8eribulin 8Paclitaxel 8Cyclophosphamide 8Epirubicin 7Gemcitabine 6Cisplatin 6tislelizumab 5apatinib 5atezolizumab 4anlotinib 4Taxes 4Nivolumab 4Docetaxel 4Bevacizumab 4toripalimab 3Vinorelbine 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Doxorubicin 3Albumin-Bound Paclitaxel 3talazoparib 2spartalizumab 2olaparib 2fluzoparib 2famitinib 2Zoledronic Acid 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Unknown × Triple Negative Breast Neoplasms × Epirubicin × Clear all
NCT04418154 2024-05-21

NeoTENNIS

Fudan University

Phase 2 Unknown
70 enrolled
Breast

Triple Negative Breast Neoplasms

NCT05491694 2022-08-08

HIFU

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
20 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04676997 2020-12-21

Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)

Shandong Cancer Hospital and Institute

Phase 2 Unknown
20 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04213898 2019-12-30

SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer

Henan Cancer Hospital

Phase 1/2 Unknown
39 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03876886 2019-03-21

The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency

ChineseAMS

Phase 3 Unknown
200 enrolled
Breast

Triple Negative Breast Neoplasms

NCT01378533 2011-12-28

The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC

ChineseAMS

Phase 3 Unknown
100 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01276769 2011-11-16

Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer

ChineseAMS

Phase 2 Unknown
80 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡